Tempest Therapeutics, Inc. (TPST)
US — Healthcare Sector
Automate Your Wheel Strategy on TPST
With Tiblio's Option Bot, you can configure your own wheel strategy including TPST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TPST
- Rev/Share 0.1414
- Book/Share 3.2385
- PB 1.8928
- Debt/Equity 1.1771
- CurrentRatio 1.7024
- ROIC -1.8561
- MktCap 22573296.0
- FreeCF/Share -7.5947
- PFCF -0.8646
- PE -0.4704
- Debt/Assets 0.4074
- DivYield 0
- ROE -3.0551
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TPST | H.C. Wainwright | Buy | Neutral | -- | -- | April 10, 2025 |
| Downgrade | TPST | Scotiabank | Sector Outperform | Sector Perform | -- | -- | April 10, 2025 |
News
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
TPST
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company's novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP).
Read More
About Tempest Therapeutics, Inc. (TPST)
- IPO Date 2012-11-12
- Website https://www.tempesttx.com
- Industry Biotechnology
- CEO Mr. Stephen R. Brady J.D., LLM
- Employees 24
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.